How does clinical trial efficacy work (simply put)?

Post date: 2020-12-02 13:05:54
Views: 187
Confused about the data provided on the recent COVID studies, and why they mean vaccines were judged to be 95% effective

The Pfizer and Moderna press releases (Pfizer's linked here) provide three main pieces of data: the number of trial participants, the number of participants who contracted the virus, and the number of participants contracting the virus who were in the control group, receiving a placebo. (Apologies for any mistakes in terminology or anything else I'll be making here.)

So for Pfizer's trial, there were more than 43,000 participants, 170 of them contracting COVID, and 8 of them were in the vaccine group, meaning 162 were in the placebo group. 8/162 is ~5%.

The press releases don't say that this is why the vaccines are judged to be 95% effective, though papers like the Washington Post connect the dots. But how is this not the wrong way to judge effectiveness? Wouldn't the right way be to say 162 out of 16,200, e.g., taking the placebo contracted it, and that's 1%, and 8 of let's say 16,200 receiving the vaccine contracted it, and that's 5% of 1%, meaning the vaccine is 95% effective?
Number of Comments
Please click Here to read the full story.
 
Other Top and Latest Questions:
Palantir rallies 15% for the week as Iran war boosts prospects, muting Anthropic concern
How China is challenging the U.S. to become the next great space power
Dow falls 450 points, posts worst week in nearly a year as oil tops $90, jobs data disappoints: Live updates
2 confidence-building tools for parents to set kids up for 'a lifetime of success,' from a mental performance coach
Iran's internet blackout extends into second week: NetBlocks
Guided tours of museums and sights in Paris?
FDA vaccine head will step down in April after string of controversial decisions
Jan. 6 plaque honoring police officers quietly installed at the Capitol after a 3-year delay
One year after Trump’s sovereignty threats, Canadians keep ‘elbows up’
'E-shaped' economy is replacing a K-shaped one in 2026, economist says: The middle class is 'spending in a nervous way' now